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ABSTRACT
Trastuzumab has been shown to be an effective therapy
for women with breast cancer that overexpresses the
human epidermal growth factor receptor 2 (HER2) pro-
tein. In the pivotal metastatic breast cancer trials, car-
diac dysfunction was observed in women treated with
trastuzumab and chemotherapy. The incidence and
severity of cardiac dysfunction was greatest among
patients who received trastuzumab in combination
with anthracycline-based therapy. Those findings in-
fluenced the design of subsequent trastuzumab trials
to include prospective evaluations of cardiac effects
and protocols for cardiac monitoring and management.
The risk of cardiotoxicity has also driven efforts to
develop non-anthracycline-based regimens for women
with HER2-positive breast cancers.
With the increasing use of trastuzumab, particu-
larly in the curative adjuvant setting, the need for a
rational approach to the treatment and cardiac man-
agement of the relevant patient population is clear.
The mandate of the Canadian Trastuzumab Working
Group was to formulate recommendations, based on
available data, for the assessment and management
of cardiac complications during adjuvant trastuzu-
mab therapy. The panel formulated recommendations
in four areas:
• Risk factors for cardiotoxicity
• Effects of various regimens
• Monitoring
• Management
The recommendations published here are expected
to evolve as more data become available and experi-
ence with trastuzumab in the adjuvant setting grows.
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1. INTRODUCTION
Breast cancer is the most common female malignancy
in the world 1. Globally, it accounts for 7% of all can-
cer-related deaths and 22% of all new cancer diag-
noses in women. In Canada, breast cancer is similarly
the most common cancer in women, with more than
22,000 new diagnoses every year. Breast cancer is
responsible for the deaths of more than 5000 Cana-
dian women annually, more than any other malig-
nancy except lung cancer 2.
Approximately 20%–25% of breast cancers
overexpress or amplify human epidermal growth fac-
tor receptor 2 (HER2) 3,4. This cell-surface protein,
which is involved in normal cellular growth and dif-
ferentiation, is a member of the HER (ErbB) family of
transmembrane receptor tyrosine kinases. Tumours
that overexpress the HER2 protein or that amplify the
HER2/neu gene are associated with an aggressive
disease course and a poor prognosis, with high risk
of recurrence and metastasis 3–6.
Trastuzumab, a humanized monoclonal antibody,
was developed to target HER2 7. When used in combi-
nation with taxanes in the first-line treatment of meta-
static breast cancer, trastuzumab improves survival
and quality of life 8–10. Trastuzumab has also shown
efficacy as monotherapy in metastatic breast cancer,
both as first-line treatment and in patients whose
tumours failed to respond to one or more chemothera-
pies 11–13.
Motivated by the considerable antitumour effect
of trastuzumab in HER2-positive metastatic breast can-
cer, four major international studies of trastuzumab
in the adjuvant setting were initiated during 2000–
2001. In Canada, early results of those trials led to the
approval, in 2006, of trastuzumab for the adjuvant
treatment of HER2-positive breast cancer 14. Results of
the trastuzumab adjuvant trials are summarized later
in this paper.
During the pivotal metastatic breast cancer tri-
als of trastuzumab, an unexpected toxicity—cardiac
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dysfunction—was observed in women treated with
trastuzumab and chemotherapy 10. The incidence
and severity of cardiac dysfunction was greatest
among patients who received trastuzumab in com-
bination with an anthracycline. Those findings in-
fluenced the design of subsequent trastuzumab trials
to include prospective evaluations of cardiac effects
and cardiac monitoring and management protocols.
They also drove efforts to develop non-anthracy-
cline treatment regimens for HER2-positive breast
cancers 15,16.
With the increasing use of trastuzumab, particu-
larly in the curative adjuvant setting, the need for a
rational approach to the treatment and cardiac man-
agement of the relevant patient population is clear.
The mandate of the Canadian Trastuzumab Working
Group was to formulate, based on available data, rec-
ommendations for cardiac management during adju-
vant trastuzumab therapy. The recommendations
published here are expected to evolve as more data
become available and as experience with trastuzu-
mab in the adjuvant setting grows.
2. DEVELOPMENT OF RECOMMENDATIONS
The Canadian Trastuzumab Working Group (seven
oncologists and two cardiologists) met in Toronto for
a full-day conference in March 2007. The panel re-
viewed results of the adjuvant trastuzumab trials, as
well as the cardiac parameters used in those trials—
including cardiac eligibility criteria, definitions of
cardiac effects, monitoring protocols, and manage-
ment strategies and results. Based on that informa-
tion, recommendations were formulated for
monitoring and management of cardiac side effects
during adjuvant trastuzumab therapy. An outline—
and then a draft manuscript of the recommenda-
tions—was reviewed by three panel members, and
the full manuscript was reviewed by all panel mem-
bers. Recent clinical trial results (released since March
2007) were incorporated into the present document.
The recommendations discussed here will be updated
as additional evidence becomes available.
Development of the recommendations and the
present manuscript were funded by an unrestricted
educational grant from Roche Canada. The authors
are responsible for the recommendations and the con-
tent of the manuscript, with no restrictions set by the
sponsor.
The recommendations are made in four sections:
• Risk factors for cardiotoxicity
• Effects of various regimens
• Monitoring
• Management
Each section begins with a bulleted list of key
recommendations, followed by a discussion of the
available evidence, of the panel’s rationale for the
recommendations, and of any points on which con-
sensus was lacking.
3. THE TRASTUZUMAB ADJUVANT TRIALS
Four major adjuvant trials—HERA (the Herceptin
Adjuvant trial), the National Surgical Adjuvant Breast
and Bowel Project (NSABP) B-31 trial, the North Cen-
tral Cancer Treatment Group (NCCTG) N9831 trial, and
the Breast Cancer International Research Group
(BCIRG) 006 trial—investigated various adjuvant ap-
proaches with trastuzumab. Between them, these tri-
als enrolled more than 13,000 women with
HER2-positive early breast cancer 17 (Table I). Results
indicated that adjuvant trastuzumab reduces the
3-year risk of recurrence by nearly half in such pa-
tients. The benefit was similar across the trials de-
spite differences in patient populations, chemotherapy
regimens, and sequencing of treatment 17. In addition,
a significant survival benefit was seen across all tri-
als (Table II).
Based on the data from these pivotal adjuvant
trastuzumab trials demonstrating significant disease-
free survival and overall survival benefits, trastuzu-
mab was adopted as the standard of care in
HER2-positive early breast cancer.
Comparisons between studies of trastuzumab-
related cardiotoxicity are difficult. The studies used
different entry criteria for cardiac function and car-
diovascular risk, different definitions of cardiac dys-
function, and different parameters to assess cardiac
safety. Nonetheless, each of the major trials showed
a clear signal for increased cardiotoxicity with adju-
vant trastuzumab. In absolute terms, the increased
risk for New York Heart Association (NYHA) grades III
and IV heart failure (see Appendix A) was 0.4%–3.3%;
in relative terms, risk increased by a factor of 5–10.
The rate of asymptomatic decline by more than 10%
in left ventricular ejection fraction (LVEF) ranged from
a high of 18% in BCIRG 006 to a low of 3% in HERA
(Tables III and IV) 18,20,24–27.
It is also clear that, although symptomatic heart
failure may respond to heart failure medications 15,
the drop in LVEF in trastuzumab-treated patients does
not necessarily fully recover to baseline. Although it
is reassuring that, in these trials, no deaths from heart
failure have occurred in trastuzumab-treated patients
to date, the long-term consequences of the identified
decreases in LVEF, both symptomatic and asymptom-
atic, are as yet largely unknown. The syndrome of
trastuzumab-associated cardiotoxicity exhibits clini-
cal features that differ from those of classic anthra-
cycline-associated cardiotoxicity (see Appendix B).
3.1 The HERA Trial
The HERA trial compared 1 or 2 years of trastuzumab
with observation alone in patients with HER2-positive
breast cancer who had completed locoregional therapyPRACTICE GUIDELINE SERIES
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and at least 4 cycles of neoadjuvant or adjuvant che-
motherapy 32. Treatment with trastuzumab for 1 year
following adjuvant chemotherapy was associated with
a significant overall survival benefit after a median
follow-up of 2 years. The unadjusted hazard ratio for
risk of death with trastuzumab as compared with risk
of death with observation alone was 0.66 [95% confi-
dence interval (CI): 0.47 to 0.91; p = 0.0115] 18.
The incidence of cardiac endpoints was higher
in the trastuzumab group than in the observation
group: severe heart failure (NYHA grades III and IV)
was 0.60% as compared with 0.00%; symptomatic
heart failure (including NYHA grade II heart failure)
was 2.15% as compared with 0.12%; and confirmed
significant decline in LVEF was 3.04% as compared
with 0.53% 24. No evidence of cumulative cardio-
toxicity beyond 1 year was observed 18,32. Most pa-
tients with cardiac dysfunction experienced symp-
tomatic improvement and at least partial recovery of
LVEF less than 6 months after withdrawal of trastuzu-
mab and initiation of medical treatment with angio-
tensin converting-enzyme (ACE) inhibitors and
beta-blockers 24.
The authors of a recent detailed analysis of car-
diac endpoints in the HERA trial suggested that the
benefit of trastuzumab continues to increase into the
2nd year of follow-up, while the cumulative incidence
of any type of cardiac endpoint appears stable after
completion of trastuzumab at 12 months 24. However,
they also acknowledge that the median follow-up in
their report is only 12 months. Longer-term data will
be needed to confirm their findings.
TABLE II Trastuzumab (H) adjuvant trials: efficacy
Trial Patients Disease-free survival (%) Overall survival (%)
(n) H arm Non-H arm H arm Non-H arm
HERA 18 5102 80.6 74.3 92.4 89.7
(2-Year median follow-up) Absolute benefit: 6.3% Absolute benefit: 2.7%
HR: 0.64 (p<0.0001) HR: 0.66 (p=0.0115)
Joint analysis 19 3968 85.9 73.1 92.6 89.4
(NCCTG N9831, NSABP B-31; Absolute benefit: 13% Absolute benefit: 3.2%
3-Year median follow-up) HR: 0.48 (p<0.00001) HR: 0.65 (p=0.0007)
BCIRG 006 20 AC®TH 3222 83 77 92 86
(3-Year median follow-up) vs. Absolute benefit: 6% — a
AC®TH R : 0.61 (p<0.0001) HR: 0.59 (p=0.004)
TCbH 82 77 91 86
vs. Absolute benefit: 5% — a
AC®TH R : 0.67 (p=0.0003) HR: 0.66 (p=0.017)
a Absolute benefit value not available.
HERA = Herceptin Adjuvant Trial; HR = hazard ratio; NCCTG = North Central Cancer Treatment Group; NSABP = National Surgical Adjuvant
Breast and Bowel Project; BCIRG = Breast Cancer International Research Group; AC = doxorubicin–cyclophosphamide; T = docetaxel.
TABLE I Trastuzumab (H) adjuvant trials: patient characteristics
Patient characteristics HERA 18 Joint analysis 19 BCIRG 006 20
Observation H (NCCTG N9831, NSABP B-31) AC®TA C ®TH TCbH
(%) (%) Control H (%) (%) (%)
(%) (%)
Age
<50 years 52 52 51 51 52 52 54
³50 years 48 48 49 49 48 48 46
ER+ or PR+ (or both) 50 50 53 52 54 54 54
Nodal status
Node-negative 33 32 13 11 29 29 29
1–3 Nodes positive 29 29 52 54 38 38 39
³4 Nodes positive 28 28 41 41 33 33 33
Tumour size
£2 cm 40 40 38 41 38 40
>2 cm 49 58 61 59 62 60
HERA = Herceptin Adjuvant Trial; NCCTG = North Central Cancer Treatment Group; NSABP = National Surgical Adjuvant Breast and Bowel
Project; BCIRG = Breast Cancer International Research Group; AC = doxorubicin–cyclophosphamide; T = docetaxel; ER+ = estrogen receptor–
positive; PR+ = progesterone receptor–positive.MACKEY et al.
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In terms of risk factors for trastuzumab-associ-
ated cardiotoxicity in the HERA trial, patients who de-
veloped heart failure were treated with higher
cumulative doses of doxorubicin (287 mg/m2 vs.
257 mg/m2) or epirubicin (480 mg/m2 vs. 422 mg/m2),
and had a lower LVEF (55%–60% vs. ³60%, and 60%–
65% vs. ³65%) and a higher body mass index (> 25
vs. 20–25) at screening. No associations were found
between cardiac endpoints and older age, previous
cardiac disease, hyperlipidemia, or hypertension. The
investigators caution that analyses of potential risk
factors are exploratory and based on a small number
of cardiac events 24.
3.2 Joint Analysis: NSABP B-31 and NCCTG 9831
The NSABP B-31 trial compared doxorubicin and
cyclophosphamide followed by paclitaxel every
3 weeks (AC®P, group 1) with the same regimen plus
52 weeks of trastuzumab beginning with the first dose
of paclitaxel (AC®PH, group 2). The NCCTG N9831 trial
compared three regimens: doxorubicin and cyclo-
phosphamide followed by weekly paclitaxel (AC®P,
group A), the same regimen followed by 52 weeks of
trastuzumab after the paclitaxel (AC®P®H, group B),
and the same regimen plus 52 weeks of trastuzumab
initiated concomitantly with the paclitaxel (AC®PH,
group C). The studies were amended to include a joint
analysis comparing group 1 plus group  A (the con-
trol group) with group 2 plus group C (the trastuzu-
mab group). Group B was excluded from the joint
analysis because trastuzumab was not given concur-
rently with paclitaxel 25.
An interim joint efficacy analysis of these trials
showed that the absolute difference in disease-free
survival between the trastuzumab group and the con-
trol group was 12% at 3 years. Trastuzumab therapy
was associated with a 33% reduction in the risk of
death (p = 0.015) 25. Following publication of the re-
port, patients who had been randomized to AC®P and
who were less than 6 months from completion of their
chemotherapy were made eligible to receive adju-
vant trastuzumab 19.
A recent efficacy update showed 4-year disease-
free survival rates of 85.9% in the trastuzumab group
Table III Trastuzumab (H) adjuvant trials: cardiac safety
Trial Arm Baseline Severe heart Asymptomatic HH Cardiac death
LVEF failure a LVEF declines b discontinued c never started c (n)
(%) (%) (%) (%) (%)
HERA 18,24 Chemo ³55 0 0.5 4.3 NA 1
Chemo + H 0.60 3 0
NSABP-31 25,26 AC®P ³50 0.9 d 1
AC®PH (LLN) 3.8 d 0
NCCTG N9831 25 AC®P ³50 0.3 d 14.2 18.9 e 6.7 1
AC®P®H (LLN) 2.5 d 1
AC®PH 3.5 d 0
BCIRG 006 20,27 AC®T ³50 0.4 10 0
AC®TH (LLN) 1.9 18 NA 2.2 0
TCbH 0.4 8.6 0 0
a New York Heart Association grade III or IV and decrease in left ventricular ejection fraction of 10 percentage points or more from baseline
and to under 50%; does not include death 24.
b New York Heart Association grade I or II and decrease in left ventricular ejection fraction of 10 percentage points or more below baseline
and to under 50% 24.
c Because of cardiac problems.
d Cumulative incidence.
e Asymptomatic decline in left ventricular ejection fraction (14.2) plus heart failure or other adverse cardiac effect (4.7).
LVEF = left ventricular ejection fraction; HERA = Herceptin Adjuvant Trial; Chemo = chemotherapy;  NA = not available; NSABP = National
Surgical Adjuvant Breast and Bowel Project; AC = doxorubicin–cyclophosphamide; P = paclitaxel; LLN = lower limit of normal; NCCTG =
North Central Cancer Treatment Group; BCIRG = Breast Cancer International Research Group; T = docetaxel; Cb = carboplatin.
TABLE IV Trastuzumab (H) adjuvant trials: relative risk (RR) of seri-
ous, life-threatening, or fatal cardiac events 28
Trial Treatment Control RR
(n)( % ) ( n)( % )
HERA 18 10 0.6 1 0.1 9.97
Joint analysis 19 51 3.1 5 0.3 10.38
(NCCTG N9831, NSABP B-31)
BCIRG 006 20
AC®TH 20 1.9 4 0.4 5.0
TCbH 4 0.4 4 0.4 1.0
HERA = Herceptin Adjuvant Trial; NCCTG = North Central Cancer
Treatment Group; NSABP = National Surgical Adjuvant Breast and
Bowel Project; BCIRG = Breast Cancer International Research Group;
AC = doxorubicin–cyclophosphamide; T = docetaxel; Cb =
carboplatin.PRACTICE GUIDELINE SERIES
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and 73.1% in the control group (p < 0.00001) 19.
Overall survival rates at 4 years were 92.6% and
89.4% respectively (p = 0.0007). The investigators
concluded that the benefit of AC®PH is maintained
with longer follow-up. The hazard of disease recur-
rence is reduced by 52% (p < 0.00001) and the haz-
ard of death is reduced by 35% (p = 0.0007), despite
the fact that 21% of patients randomized to the con-
trol group received trastuzumab.
An initial assessment of cardiac dysfunction in
these trials showed that the 3-year cumulative inci-
dence of cardiac events (grades III and IV heart fail-
ure or cardiac death) was 4.1% in the trastuzumab
group and 0.8% in the control group in NASBP B-31
and 2.9% with trastuzumab and 0% in the control
group in NCCTG N9831 25,33. With 2 years of additional
follow-up, the cumulative incidence of cardiac events
in the trastuzumab group in NSABP B-31 remained
essentially unchanged at 3.8% (Table V) 26,34. How-
ever, 14.2% of patients had to stop trastuzumab be-
cause of an asymptomatic decline in LVEF, and a total
of 18.9% discontinued trastuzumab because of car-
diac problems (Table III). These analyses also ex-
cluded patients who had already developed
cardiotoxicity from anthracyclines at the completion
of their 4 cycles of AC chemotherapy (6.7% of the
initial group) and who were therefore ineligible to
receive adjuvant trastuzumab. The absolute rate of
cardiotoxicity in an intent-to-treat analysis would be
somewhat higher.
3.3 BCIRG 006
The BCIRG 006 trial compared adjuvant doxorubicin
and cyclophosphamide followed by docetaxel (AC®T)
to the same regimen with trastuzumab added concur-
rently with the docetaxel (AC®TH) and to docetaxel,
carboplatin, and trastuzumab (TCbH). (Trastuzumab
was given for 1 year on both arms that used it.) Re-
sults of the second interim analysis showed that 3-year
disease-free survival rates were 77% for AC®T, 83%
for AC®TH, and 82% for TCbH (AC®TH vs. AC®T, p <
0.0001; TCbH vs. AC®T, p = 0.0003). Overall survival
rates were 86% for AC®T, 92% for AC®TH, and 91%
for TCbH (AC®TH vs. AC®T, p = 0.004; TCbH vs. AC®T,
p = 0.017) 20. This was the third trial to report sig-
nificant disease-free survival and overall survival
benefits.
No cardiac deaths were observed after 3 years of
follow-up in this trial. Patients with grades III and IV
heart failure numbered 4 on the AC®T arm (of 1050),
20 on the AC®TH arm (of 1068), and 4 on the TCbH
arm (of 1056), with a p value of 0.0015 for AC®TH
vs. TCbH. The percentage of patients with a greater-
than-10% relative decline in LVEF was 10% on the
AC®T arm, 18% on the AC®TH arm, and 8.6% on the
TCbH arm (all differences statistically significant) 20.
3.4 The Finland Herceptin Trial
A Finnish trial, FinHER, much smaller in scope than
the four international adjuvant trials, treated women
with early breast cancer with 3 cycles of docetaxel
or vinorelbine, followed by 3 cycles of 5-fluorou-
racil, epirubicin, and cyclophosphamide. A subgroup
of 232 patients with HER2-positive breast cancer were
further randomized to 9 weekly trastuzumab
infusions 35.
Within the subgroup of HER2-positive patients,
women who received trastuzumab had a better rate
of 3-year recurrence-free survival than women who
did not receive trastuzumab (89% vs. 78%). No dif-
ference in overall survival was observed. Trastuzu-
mab was not associated with decreased LVEF or cardiac
failure 35.
4. RECOMMENDATIONS FOR ASSESSMENT
AND MANAGEMENT OF CARDIAC
COMPLICATIONS DURING ADJUVANT
TRASTUZUMAB THERAPY
Each subsection begins with a list of key recommen-
dations. A discussion of the available evidence and
the panel’s rationale for the recommendations then
follows.
4.1 Risk Factors for Cardiotoxicity
• Risk factors that exclude patients from treatment
with trastuzumab are existing heart failure or
LVEF < 50% [or below the facility’s lower limit of
normal (LLN)], or both.
• Trastuzumab may be considered in patients
with a LVEF < 50% if their risk of disease re-
currence is very high.
• Risk factors that require special consideration
include
• ischemic heart disease or significant
valvulopathy,
• a baseline LVEF 50%–55% before trastuzumab
therapy,
TABLE V Five-year cumulative incidence of cardiac events in the
National Surgical Adjuvant Breast and Bowel Project B-31 trial 26
Years Cumulative incidence of At risk
post day 1, cardiac events (%) (n)
cycle 5 Arm 1 a Arm 2
(AC®T)( AC®TH)
1.0 0.5 3.3 1678
2.0 0.6 3.6 1271
3.0 0.9 3.8 907
4.0 0.9 3.8 569
5.0 0.9 3.8 186
a Arm 1 events among crossover patients censored.
AC = doxorubicin–cyclophosphamide;  T = docetaxel;  H =
trastuzumab.MACKEY et al.
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• a decrease in LVEF of more than 15% while on
trastuzumab therapy, even if LVEF remains
above the LLN 27.
Discussion Cardiac eligibility criteria were similar,
but not identical, across the four major adjuvant tri-
als. The NSABP B-31, NCCTG 9831, and BCIRG 006 trials
all required patients to have a LVEF ³ LLN (50%) and
no past or active cardiac disease (including myocar-
dial infarction, heart failure, cardiomyopathy, angina
pectoris or arrhythmia requiring medication, severe
conduction abnormality, clinically significant valvu-
lar disease, uncontrolled hypertension, ventricular
hypertrophy, or cardiomegaly on chest radio-
graph) 20,25.
Similarly, HERA excluded patients with a history
of cardiac disease 24. However, the acceptable lower
limit for LVEF was higher in HERA, at ³55%. Patients
enrolled in HERA also received trastuzumab after com-
pleting chemotherapy; patients reported in the other
three trials had been enrolled with normal cardiac
function (LVEF ³ 50%) before receiving any systemic
therapy for breast cancer. The cardiac-specific report
on  HERA suggests that these factors may have con-
tributed to the lower incidence of cardiac dysfunc-
tion in the HERA trial. That is, patients who experienced
a drop in LVEF following anthracycline-based chemo-
therapy would not have been eligible for the HERA
trial 24.
The NSABP B-31 5-year update identified four risk
factors for heart failure in trastuzumab-treated
patients 26:
• Age (50–59 years, 5.1%; ³60 years, 5.4%)
• Use of hypertensive medications (6.8%)
• Baseline LVEF values of 50%–54% (12.9%)
• Post-anthracycline chemotherapy LVEF values of
50%–54% (12.6%)
The number of patients over 60 years of age in
that trial was 148; the number on hypertensive medi-
cations was 192; the number that had a baseline LVEF <
54% was 70; and the number that had a post-anthra-
cycline LVEF < 54% was 111.
The HERA trial results also showed that a lower
baseline LVEF value and a high body mass index are
risk factors for heart failure in trastuzumab-treated
patients. However, in contrast to NSABP B-31, HERA
observed no association between cardiac endpoints
and increased age, previous cardiac disease, hyper-
lipidemia, or hypertension 24.
Both HERA and NCCTG N9831 investigated the use
of radiotherapy in trastuzumab-treated patients. In the
HERA trial, previous radiotherapy did not increase the
incidence of cardiac dysfunction 24. In NCCTG N9831,
concurrent radiotherapy and trastuzumab did not in-
crease the incidence of cardiac events or radiotherapy-
associated adverse events, with the exception of
leucopenia 36. The investigators cautioned that longer
follow-up is required to determine whether any long-
term cardiotoxicity emerges.
4.2 Effects of Various Regimens on Cardiotoxicity
• The data are insufficient to make any formal state-
ments regarding the relative cardiotoxicity of
concurrent as compared with sequential treatment
regimens, or of anthracycline use of in patients
with cardiac risk factors.
• On the basis of HERA and of the NCCTG N9831
comparison of group B (AC®T®H) and group C
(AC®TH), sequential anthracycline–taxane–tras-
tuzumab regimens may possibly be less car-
diotoxic than concurrent regimens that include
anthracyclines—that is, anthracycline–taxane+
trastuzumab).
• Direct randomized evidence, as reported in the
BCIRG 006 trial, suggests that the anthracycline-
free  TCbH regimen has a rate of severe
cardiotoxicity that is one fifth that of the anthra-
cycline-containing AC®TH regimen (incidence of
grades III and IV heart failure 0.4% vs. 1.9%) 20.
• Until such time as optimal duration of trastuzu-
mab therapy has been established by ongoing ad-
juvant trials [PHARE (Protocol of Herceptin
Adjuvant with Reduced Exposure), HERA, and the
Danish FinHER replacement study], patients with
early breast cancer should be treated with trastu-
zumab for 1 year (less only if disease recurs) 14.
Discussion The HERA trial reported a low incidence
(0.6%) of severe heart failure despite the use of
anthracycline-based chemotherapy in most patients.
That finding may be the result of contributions from
two principle mechanisms:
• Selection of patients with a LVEF ³ 55% after ad-
juvant chemotherapy (the incidence of heart fail-
ure in the HERA trial patients was reduced relative
to other trials that used a pre-chemotherapy LVEF
cut-off of 50%)
• Timing of trastuzumab administration (trastuzu-
mab was typically administered some months
after completion of anthracycline chemo-
therapy) 18,24
However, differences between the trial designs
make this comparison informal at best.
The only adjuvant trial that directly compared
concurrent with sequential trastuzumab treatment is
the NCCTG N9831 trial. Two preliminary reports on the
efficacy and cardiotoxicity of concurrent versus se-
quential therapy have been published. One report com-
pared group B (AC®T®H) with group C (AC®TH) and
suggested that sequential treatment may be less ef-
fective than concurrent treatment (Perez PA, Suman
VJ, Davidson N, Martino S, Kaufman P. Advances in
monoclonal antibody therapy for breast cancer: furtherPRACTICE GUIDELINE SERIES
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analysis of NCCTG-N9831. Presented at the 41st
Annual Meeting of the American Society of Clinical
Oncology; May 13–17, 2005; Orlando, Florida). How-
ever, that interim analysis (requested by the data moni-
toring committee) had low statistical power; longer
follow-up is needed to definitively address the ques-
tion. The planned cardiac safety analysis of NCCTG
N9831 showed that the incidence of grades III and IV
heart failure was 3.3% with concurrent treatment and
2.2% with sequential treatment 37.
Results from the BCIRG 006 trial suggest that the
TCbH regimen is less cardiotoxic, both acutely and
with 3-year follow-up, than the AC®TH) combina-
tion 20. These data are the only available random-
ized comparison of an anthracycline-based with a
non-anthracycline-based trastuzumab regimen, and
they demonstrate a rate of grades III and IV heart fail-
ure (20 patients, 1.9%) that is higher by a factor of 5
with AC®TH than with TCbH (4 patients, 0.4%). Panel
members favoured the non-anthracycline TCbH regi-
men for patients with pre-existing risk factors for
cardiotoxicity.
The FinHER trial treated 232 patients with trastu-
zumab for only 9 weeks. Analysis showed a relapse-
free survival benefit and no clinical cardiotoxicity,
but no significant difference in overall survival at
3 years 35. The HERA trial includes a third arm in which
patients are receiving 2 years of trastuzumab 32. The
first results are expected later in 2008. The panel
agreed that until such time as data become available
regarding either shorter or longer durations of therapy,
early breast cancer patients should be treated with
trastuzumab for 1 year (less only if disease recurs).
That decision accords with the product monograph 14,
the major adjuvant clinical trials, and the major clini-
cal guidelines (Cancer Care Ontario 38, British Co-
lumbia Cancer Agency 39, National Comprehensive
Cancer Network 40, Comité de l’évolution des pra-
tiques en oncologie 41, and St. Gallen’s 42). The guide-
lines also all indicate that trastuzumab is the standard
of care for patients with node-positive disease or
node-negative disease with a tumour size larger than
1 cm, regardless of hormone receptor status.
4.3 Monitoring
Given the relatively short follow-up times of the ad-
juvant trastuzumab trials and the incomplete recov-
ery of cardiac function seen in those trials, even when
heart failure medications are used, the panel empha-
sized the need for careful selection of patients, and
consistent cardiac monitoring at 3-month intervals
during the 1-year period of trastuzumab therapy.
• Assessment of cardiac function per established
protocols is critical and must be endorsed for all
patients.
• Either echocardiography or multiple gated acqui-
sition scan should be used to establish baseline
LVEF. The same imaging modality should be used
at follow-up.
• Multiple gated acquisition scanning is gener-
ally more widely available in Canada and may
be subject to less variability.
• If echocardiography is used, the same tech-
nique must be used for each assessment. The
preferred technique is the Simpson method.
• The LVEF should be assessed before trastuzumab
treatment is started (and after chemotherapy, for
sequential regimens) and should be repeated
every 3 months until completion of trastuzumab
therapy. Each patient will therefore undergo a
minimum of 5 LVEF assessments: immediately
before trastuzumab is initiated and at 3, 6, 9, and
12 months in the course of therapy.
• Patients who experience cardiac symptoms or
a greater than 10% absolute asymptomatic
decline in LVEF while receiving trastuzumab
may continue to undergo annual cardiac as-
sessments following completion of trastuzu-
mab treatment.
• At this time, no evidence exists to support fur-
ther cardiac monitoring of patients who have
completed chemotherapy and trastuzumab
treatment with no cardiac symptoms and no
signs of substantial (greater than 10% abso-
lute decrease), but asymptomatic, LVEF decline.
• The cardiac monitoring requirements outlined in
the present article should be understood to rep-
resent the minimum monitoring requirements. Pa-
tients with cardiotoxicity or other risk factors
may require more frequent and more stringent
monitoring.
Discussion As new therapies move from phase III
clinical trials to the clinic, patient selection criteria
and monitoring generally become more flexible. Pa-
tients who would not have been eligible for clinical
trials may be offered treatment, whether in hope of a
cure or because of a lack of other options. Monitor-
ing often becomes more infrequent and irregular with-
out the standardized requirements of trial-mandated
protocols. Panel members reported anecdotally that,
in their tertiary care centres, cardiac monitoring rates
of trastuzumab patients not enrolled in trials have not
always been optimal.
To ensure patient safety and optimal treatment,
rigorous monitoring of trastuzumab patients is of
paramount importance. The adjuvant trials have
shown that patients can experience a significant de-
cline in LVEF without experiencing symptoms. The
LVEF assessment schedule recommended here is based
on schedules used in the adjuvant trials. The trial
schedules varied somewhat with the regimens, but
the basic approach was to assess cardiac function
every 3 months during therapy.
The panel was divided on the need for continued
monitoring of asymptomatic patients with a normalMACKEY et al.
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LVEF after the completion of trastuzumab treatment.
Some panel members felt that annual assessments of
these patients would be advisable until more is known
about the long-term cardiac effects of trastuzumab.
Others felt that such monitoring could place an undue
burden on patients and the health care system alike,
and also perhaps expose patients to unnecessary doses
of radiation. Further long-term data are needed to
clarify this issue.
4.4 Management of Cardiotoxicity
• Management of trastuzumab-related cardiotox-
icity has two distinct aspects: withdrawal of tras-
tuzumab therapy and treatment of cardiac
dysfunction.
• The “stopping/restarting” rules used in the adju-
vant trials were effective and are recommended
(Table VI), with some modifications regarding
recommendations for a cardiology consult or
treatment of cardiac dysfunction (or both) when
appropriate.
• Symptomatic left ventricular (LV) dysfunction
must be treated per Canadian Cardiovascular
Society recommendations for heart failure treat-
ment 21:
• All patients with heart failure and a LVEF below
40% should be treated with an ACE inhibitor in
combination with a beta-blocker unless a spe-
cific contraindication exists (class I, level A
evidence).
• Some members of the panel also felt that, to
prevent further degradation of LVEF or the de-
velopment of clinical heart failure, an ACE in-
hibitor should be considered if the patient’s
LVEF is between 40% and 50%.
• Asymptomatic LV dysfunction should be treated
per the recommendations of the Canadian Cardio-
vascular Society 43:
• ACE inhibitors should be used in all asympto-
matic patients with LV dysfunction and an ejec-
tion fraction below 40% (class I, level A evidence
for ejection fraction below 35%; class I, level B
for ejection fraction between 35% and 40%).
• Some members of the panel also felt that an
ACE inhibitor should be considered if LVEF is
below 50%.
• Beta-blockers should be considered in all pa-
tients with asymptomatic LV dysfunction and a
LVEF below 40% (if prior myocardial infarc-
tion, class I, level B evidence; if no myocar-
dial infarction, class IIA, level C).
• Initiation of pharmacotherapy for trastuzumab-
related cardiotoxicity must be carried out on an
accelerated schedule, because the normal titra-
tion schedules can take several months to reach
the optimal therapeutic dosage (Table VII).
• The data are insufficient to make a definitive rec-
ommendation regarding duration of treatment for
cardiac dysfunction in trastuzumab patients (see
the Discussion). The duration of treatment with
cardiac medication must be individualized.
• Following withdrawal of trastuzumab therapy
because of cardiac dysfunction, trastuzumab may
be re-initiated on the basis of the same LVEF guide-
lines as the original initiation of therapy.
Discussion Management of trastuzumab-related
cardiotoxicity has two distinct aspects: withdrawal
of trastuzumab therapy and treatment of cardiac dys-
function. The “stopping/restarting” rules used in the
adjuvant trials were effective. The panel recommends
the NSABP B-31 protocol (Table VII), with some modi-
fications to include recommendations for a cardiol-
ogy consult or treatment of cardiac dysfunction (or
both) when appropriate.
Treatment of trastuzumab-related cardiotoxicity
is a controversial subject. Patients who developed LV
dysfunction in the adjuvant trastuzumab trials were
not treated in a systematic manner. Trastuzumab-re-
lated cardiotoxicity does seem to be partially revers-
ible when trastuzumab is withdrawn and medical
therapy is initiated for symptomatic heart failure 15.
The panel recommended withdrawal of trastuzumab
and initiation of medical therapy for these reasons:
• Standard therapy for LV dysfunction and heart
failure may hasten recovery after withdrawal of
trastuzumab 44.
• Because of the longer life expectancy of patients
with early-stage breast cancer, consideration of
the potential long-term cardiotoxicity of trastu-
zumab is imperative. At this time, the longest
reported adjuvant trastuzumab experience is only
4 years 20,26. The median reported follow-up in
HERA is 2 years, and in BCIRG 006 and the joint
analysis, it is 3 years.
• Beta-blockers and ACE inhibitors have been shown
to improve survival in heart failure arising from
many causes; they are the cornerstone of heart
failure therapy 21,43.
The question of duration of therapy for cardio-
toxicity is also controversial and may not be resolved
for some time. Cardiology guidelines support con-
tinued use of therapy after a diagnosis of LV dysfunc-
tion 21,43. However, oncologists may be reluctant to
put relatively young and otherwise healthy women
on lifelong therapy for what may be a short-term or
self-limiting side effect of cancer therapy. More long-
term data are needed to clarify this issue.
In the absence of long-term data on the natural
history of trastuzumab-associated cardiotoxicity, the
duration of therapy is left to the judgment of the treat-
ing clinician (oncologist, cardiologist, family practi-
tioner) and may be determined by factors such as the
degree of LV dysfunction, patient preference and
symptoms, and degree of functional recovery.PRACTICE GUIDELINE SERIES
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5. CONCLUSIONS
The benefits of trastuzumab in HER2-positive early
breast cancer are well established. In early breast can-
cer, trastuzumab reduces the 3-year risk of recurrence
by nearly half and the risk of death by one third. With
the use of trastuzumab increasing, the need to opti-
mize the approach to treatment and management of
trastuzumab-related cardiotoxicity is clear. The man-
date of the Canadian Trastuzumab Working Group was
to formulate recommendations, based on available
data, for cardiac management during adjuvant trastu-
zumab therapy. The recommendations set out here are
expected to evolve as more data accrue and experi-
ence with trastuzumab in the adjuvant setting grows.
6. GUIDELINE DATE
This guideline was completed December 11, 2007.
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APPENDIX A HEART FAILURE AND THE NEW
YORK HEART ASSOCIATION FUNCTIONAL
CLASSIFICATION
Heart failure 21–23 is a complex clinical syndrome in
which abnormal heart function results in, or increases
the subsequent risk of, clinical symptoms and signs
of low cardiac output or pulmonary or systemic con-
gestion (or both) 22. Heart failure may be the result of
any number of cardiac disorders, but most patients
with heart failure experience symptoms because of
an impairment of left ventricular (LV) myocardial
function. Left ventricular dysfunction begins with
some injury to, or stress on, the myocardium; it is
generally progressive, even in the absence of addi-
tional insults to the heart.
The progressive nature of LV dysfunction may be
described in terms of cardiac remodelling: over time,
the chamber becomes less ovoid and more spherical;
it dilates and hypertrophies. Initially compensatory,
these changes eventually increase diastolic stiffness
and wall tension. Hemodynamic stresses on the walls
of the heart increase and mechanical performance
decreases. Because not all patients have volume over-
load at the time of initial or subsequent evaluation,
the term “heart failure” is now preferred over the older
term “congestive heart failure.”
Two classes of agents have become the recom-
mended cornerstone of therapy to delay or halt pro-
gression of cardiac dysfunction and to improve
mortality: angiotensin converting-enzyme (ACE) in-
hibitors and beta-blockers. There is compelling evi-
dence that ACE inhibitors should be used to inhibit
the rennin–angiotensin system in all heart failure
patients with LV systolic dysfunction, whether they
are symptomatic or not. The Canadian Cardiovascu-
lar Society recommends that ACE inhibitors be used
in all asymptomatic patients with a LVEF below 35%
and in all patients with symptoms of heart failure and
a LVEF below 40%.
Beta-blockers are a major advance in the treat-
ment of heart failure. Together with ACE inhibitors,
beta-blockers are now established as routine therapy
in patients with LV systolic dysfunction. The Cana-
dian Cardiovascular Society recommends that all
heart failure patients with a LVEF below 40% receive
beta-blocker therapy.MACKEY et al.
35
CURRENT ONCOLOGY—VOLUME 15, NUMBER 1
The Canadian Cardiovascular Society recom-
mends the New York Heart Association (NYHA) func-
tional classification as a simple, validated measure
of the clinical severity of heart failure 21. The NYHA
classification describes four grades of heart failure:
I No symptoms
II Symptoms with ordinary activity
III Symptoms with less than ordinary activity
IV Symptoms at rest or with any minimal activity
Common clinical presentations of heart failure
include dyspnea, orthopnea, paroxysmal nocturnal
dyspnea, fatigue, weakness, exercise intolerance, de-
pendent edema, cough, weight gain, abdominal dis-
tension, nocturia, and cool extremities.
APPENDIX B CHEMOTHERAPY-RELATED
CARDIOTOXICITY
Chemotherapy-related cardiotoxicity has been a con-
cern since the early 1970s, when anthracyclines were
first shown to be associated with cumulative, dose-
related cardiotoxicity 29. Anthracycline-related
cardiotoxicity has, for many years, been the “model”
for all forms of cardiotoxicity that reduce left ven-
tricular ejection fraction (LVEF). However, it has be-
come clear that trastuzumab-related cardiotoxicity
does not fit that model: the mechanisms and clinical
effects are distinctly different 15,30.
Anthracycline-related cardiotoxicity is largely
caused by free radical–induced oxidative stress to
cardiac muscle cells. Anthracycline-related cardio-
toxicity is cumulative and dose-related, and it re-
sults in structural damage to myocytes. The clinical
features of heart failure may take months or years
to become evident, and although the condition is
usually responsive to medical therapy, the under-
lying damage is largely irreversible. The myocar-
dium pre-exposed to an anthracycline remains more
susceptible to subsequent cardiovascular stressors,
including hypertension and the effects of trastuzu-
mab-related cardiotoxicity 15,31.
Trastuzumab-related cardiotoxicity is mediated
by interruption of the normal HER2 signalling path-
way in the heart, which maintains normal growth,
repair, and survival of cardiomyocytes. Trastuzu-
mab-related cardiotoxicity is not dose-related and
appears to be largely reversible 15,30. Evidence from
the Breast Cancer International Research Group
006 study showed that the global changes in LVEF
that occurred with adjuvant trastuzumab therapy
recovered to baseline in women receiving the non-
anthracycline docetaxel–carboplatin–trastuzumab
regimen, but the National Surgical Adjuvant Breast
and Bowel Project B-31 and Breast Cancer Inter-
national Research Group 006 studies demonstrated
incomplete  LVEF recovery in the cohorts that re-
ceived sequential anthracycline–trastuzumab
therapy 20,25–27.